Kornimate/medical-research-clean huggingface dataset:
estrogen and propofol injection pain

Conditions: Pain; Estradiol; Assisted Reproductive Techniques

Summary: this prospective observational study investigates the relationship between serum estrogen concentration and the incidence and severity of propofol injection pain (pip) in female patients undergoing general anesthesia. the study will include 90 asa i-ii female patients aged 18-45. one group will consist of ivf patients with elevated estrogen levels, while the control group will include patients with normal estrogen levels undergoing other elective procedures. pain will be assessed using a standardized four-point behavioral pain scale. the findings may enhance understanding of hormonal influences on pain and contribute to improving patient comfort during anesthesia induction.

this prospective observational study aims to evaluate the association between serum estrogen levels and the incidence and severity of propofol injection pain (pip) in adult female patients undergoing general anesthesia. although propofol is a widely used intravenous anesthetic, it frequently causes pain upon injection. estrogen is believed to play a role in modulating pain perception and inflammatory responses, yet the effects of elevated estrogen levels on pip are not well understood. the study will be conducted at a single tertiary hospital and will include 90 asa i-ii female patients aged 18-45 years. one group will consist of ivf patients with elevated serum estradiol levels due to controlled ovarian stimulation. the control group will include patients with normal estradiol levels scheduled for elective procedures under general anesthesia. preoperative serum estradiol levels will be recorded, and injection pain will be evaluated using a validated four-point behavioral pain scale based on vocal response, facial expression, limb movement, and tearfulness. anesthesia induction will follow standard clinical practice without additional interventions. pain data will be collected through routine clinical observation. the results may offer new insights into hormonal modulation of acute nociceptive responses and help improve patient experiences during anesthesia.

Eligibility criteria:
inclusion criteria: * female patients aged between 18 and 45 years * american society of anesthesiologists (asa) physical status i or ii * scheduled for surgery under general anesthesia * availability of a preoperative serum estradiol (e2) level * for group 1: undergoing ivf procedure with supraphysiological e2 levels (\>350 pg/ml) * for group 2: undergoing elective surgery with normal e2 levels (15-350 pg/ml) exclusion criteria: * asa physical status iii or iv * pregnant patients * perimenopausal women * male patients * patients younger than 18 or older than 45 years * history of psychiatric disorders * patients undergoing emergency surgery
intraoperative dexamethasone and its effect on hyperglycemia

Conditions: Diabetes Mellitus

Summary: to study the effect of intra-operative dexamethasone on the management of post-operative blood sugar in diabetic patients.


Eligibility criteria:
inclusion criteria: * documented history of type i or type ii diabetes mellitus * scheduled for surgery that requires patients to be admitted for at least 24 hours post-surgery exclusion criteria: * patients on steroid therapy * pregnant women * patients at low risk for nausea/vomiting
evaluation of the benefit provided by sessions of sophrology on the per operative management of parkinsonian patients planned for a deep brain stimulation surgery.

Conditions: Parkinson Disease; Deep Brain Stimulation

Summary: deep brain stimulation surgery, which consists of intracerebral implantation of electrodes, is considered one of the most effective techniques for controlling the motor fluctuations of parkinson's disease. the particularity of this surgery is the necessity of the awakening of the patient for the correct positioning of the electrodes, it is therefore a difficult test for the patient. medical sophrology is an ideal strategy to optimize the comfort of the patient during the operation thanks to its anxiolytic and analgesic virtues while guaranteeing the maintenance of a good patient vigilance favoring the cooperation with the operating room team. indeed, sophrology is a body-mediated set of techniques, at the crossroads between hypnosis and yoga, which makes it possible to find a balance between emotions, thoughts and behaviors. it has already been applied in other fields such as oncology, pain management, preparation for childbirth, and for 5 years at the chu of rennes for preparation for the intervention of deep brain stimulation.


Eligibility criteria:
inclusion criteria: * adult patient (age greater than or equal to 18 years) * patient with idiopathic parkinson's disease with programmed deep brain stimulation (vim target, nst, single or bilateral gpi); * planned intervention in an awake patient (implying moca\> 21 (montreal cognitive assessment)); * patient understanding the course of the study; * patient who has given informed consent in writing; * patient benefiting from a system of social insurance. exclusion criteria: * - intervention under general anesthesia; * pregnant or nursing women; * major person under protective measures (safeguard of justice, curatorship and guardianship); * person deprived of liberty. * patient having already had a practice in yoga, sophrology, hypnotherapy superior or equal to 5 sessions
loratadine for the prevention of g-csf-related bone pain

Conditions: Stem Cell Transplant Complications

Summary: the research question for the current study is: is loratadine more effective than placebo in preventing g-csf-related bone pain during autologous hematopoetic stem cell transplant in patients with lymphoma or multiple myeloma? the hypothesis is that prophylaxis with loratadine will help prevent or reduce the severity of bone pain in this setting.


Eligibility criteria:
inclusion criteria: 1. a histologically or cytologically documented lymphoma or multiple myeloma 2. next line of therapy is autologous stem cell transplant 3. adult ≥ 18 years old. 4. eastern cooperative oncology group (ecog) performance status 0-2. 5. life expectancy of at least 12 weeks. 6. the absence of any additional poorly controlled systemic disease that is directly contraindicated or places subject at significant risk, including but not limited to: congestive heart failure, diabetes mellitus, cirrhosis or liver failure, renal failure. 7. able to adhere to study protocols and visit schedules exclusion criteria: 1. hypersensitivity or intolerance to antihistamines 2. use of antihistamines within two days prior to the study period, excepting the use of single dose antihistamines during chemotherapy or blood transfusion protocols. 3. recent use of g-csf or pegfilgrastim defined as within 12 weeks of study accrual. 4. new and continued regular use of analgesics within the four days prior to the first dose of g-csf
goal setting in scs patients: a qualitative review

Conditions: Failed Back Surgery Syndrome

Summary: this is a prospective study in which the investigators will describe individual goals of patients with failed back surgery syndrome, who will be treated with spinal cord stimulation.


Eligibility criteria:
inclusion criteria: * chronic pain as a result of fbss that exists for at least 6 months with a pain intensity 5 or higher measured on numeric rating scale (nrs) * fbss patients suitable for scs * age \> 18 years * native dutch or french speeking patients exclusion criteria: * expected inability of patients to receive or properly operate the spinal cord stimulation system * history of coagulation disorders, lupus erythematosus, diabetic neuropathy, rheumatoid arthritis or morbus bechterew * active malignancy * addiction to any of the following drugs, alcohol (5e/day) and/or medication * evidence of an active disruptive psychiatric disorder or other known condition significant enough to impact perception of pain, compliance to intervention and/or ability to evaluate treatment outcome as determined by investigator * immune deficiency (hiv positive, immunosuppressiva, etc.) * life expectancy \< 1 year * local infection or other skin disorder at site of incision * pregnancy * other implanted active medical device

Keywords: spinal cord stimulation interview
survival of subjects with chronic obstructive pulmonary disease (copd)

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: the purpose of this study is to see if fluticasone 500mcg/salmeterol 50mcg can improve the survival of subjects with copd and also assess the long term safety profile of this drug.

a multicenter, randomized, double-blind, parallel group, placebo controlled study to investigate the effects of salmeterol/fluticasone 50/500mcg bd, salmeterol 50mcg bd, and fluticasone 500mcg bd, all delivered via the diskus/accuhaler inhaler, on the survival of subjects with chronic obstructive pulmonary disease over 3 years of treatment.

Eligibility criteria:
inclusion criteria: * patients with copd and fev1 \<60% of predicted normal and baseline (pre-bronchodilator) fev1/fvc ratio \<70%. * current or ex-smokers with a smoking history of at least 10 pack-years. exclusion criteria: * diagnosis of other respiratory disorders (including asthma). * requirement for long term oxygen therapy.

Keywords: mortality torch seretide advair copd
evaluation of the influence of a core muscle control-based rehabilitation program patients with multiple sclerosis

Conditions: Multiple Sclerosis; Pelvic Floor Disorders; Incontinence, Urinary

Summary: given the structural relationship of the core as a whole, in this study we propose an intervention based on the global motor control of all the structures that make up the core to assess its effectiveness on urinary incontinence, sexual dysfunction and balance, as well as its relationship with respiratory function. according to our hypothesis, a global intervention could also be taken into account during conventional treatment in the future, helping to prevent genitourinary dysfunctions derived from alterations in motor control.

main objective: to establish the effect of core motor control training on pelvic floor functionality in patients with multiple sclerosis. specific objective: to assess the effect of core motor control training on urinary incontinence. * to assess the effect of core motor control training on urinary incontinence in patients with multiple sclerosis. * to assess the effect of core motor control training on quality of life in patients with multiple sclerosis. * to assess the effect of core motor control training on sexual dysfunction in patients with multiple sclerosis. * to assess the effect of core motor control training on balance in patients with multiple sclerosis. * to test the relationship between respiratory functionality and pelvic floor dysfunctions in patients with multiple sclerosis.

Eligibility criteria:
inclusion criteria: * - age between 18 and 70 years. * confirmed diagnosis of multiple sclerosis based on mcdonald criteria, with an evolution time of more than two years (remitting or progressive) (24). * multiple sclerosis disability status scale (edss) score between 2 (minimal disability in one of the functional systems), and 7.5 (inability to take more than a few steps. limited to wheelchair and transfer support. ability to move the chair, but not all day if the chair is conventional and lacks a motor) (25, 26). * stable medical treatment for at least six months prior to surgery (26). * absence of cognitive impairment, with ability to understand instructions and score 24 or higher on the minimental test (27). * urinary incontinence as a consequence of neurological involvement. exclusion criteria: * - diagnosis of another neurological disease or musculoskeletal disorder other than ms. * diagnosis of any cardiovascular, respiratory, genitourinary, metabolic or other conditions that may interfere with this study. * having presented urinary incontinence prior to the diagnosis of ms. * have suffered an exacerbation or hospitalisation in the last 3 months before starting the assessment protocol, or during the therapeutic intervention process. * have received a course of intravenous or oral steroids 6 months prior to the start of the assessment protocol and within the intervention period of the study duration.
traditional chinese medicine combined with standard triple region for eradication of helicobacter pylori

Conditions: Helicobacter Pylori Infection

Summary: to evaluate the efficacy and safety of traditional chinese medicine (tcm) decoction and powder combined with standard triple therapy on improving eradication rate of helicobacter pylori (h. pylori).a multi-center randomized control clinical trial design was adopted in the trial.


Eligibility criteria:
inclusion criteria: * those who met chronic gastritis (chronic superficial gastritis and chronic atrophic gastritis) diagnostic criteria; * aged between 18-65 years old; * positive h. pylori infection confirmed by two or more methods of different * principles (stop using ppi, h2ra, bismuth, and antibiotics since two weeks before examination); * patients were informed consent and willing to accept corresponding treatments. exclusion criteria: * patients having chronic atrophic gastritis with severe dysplasia, upper gastrointestinal bleeding, peptic ulcers, and gastrointestinal tumors; * digestive organic disease (such as chronic pancreatitis, cirrhosis, etc.), or systemic diseases affecting intestinal motility (such as hyperthyroidism, diabetes mellitus, chronic renal insufficiency, mental, and neurological diseases, etc.); * those who were accompanied by serious heart, liver and other major organs lesions, blood diseases, and cancer (alt, ast two times higher than normal value); * those who had taken medicines that might affect h. pylori detection results within two weeks (antacids, h2ra, ppis, bismuth and antibiotics, etc.); * pregnant and lactating women; patients with history of systematic and neuropsychiatric disorders; those who had history of any drug allergy; and those who were participating in other clinical trials.
tumor cell plasticity and aggressiveness in human non-small cell lung cancer

Conditions: Lung Neoplasms; Progression

Summary: tumor cell plasticity (tcp) is a conubium of processes which lead to re-activation of developmental programs correlating with epithelial-to-mesenchymal transition, and ultimately leading to acquisition of stem cell properties and transdifferentiation potential. little is known about the molecular mechanisms governing tcp in lung adenocarcinoma (luad), i.e. the most frequent lung cancer subtype. the investigators recently identified prognostic 7-mirnas/10-mrnas signatures which accurately identified aggressive luad among patients with early-stage disease (stage i). furthermore, the investigators showed that such tumors show tcp features i.e. mesenchymal and stem-cell traits, high-metastatic potential. here, the investigators aim to explore by rnaseq and by immunophenotyping at a single-cell level (scrnaseq/abseq), the molecular features of aggressive luad to unveil the mechanisms triggering tcp. the investigators predict thier results will be relevant for the development of more effective therapeutic protocols for management of aggressive luad.


Eligibility criteria:
inclusion criteria: * patients diagnosed with lung adenocarcinoma * treatment naive * undergoing primary surgery exclusion criteria: * patients with a previous history of cancer * previously treated by chemio/immuno/radio-therapy
evaluating immune response to covid-19 vaccines in patients with cancer, transplant or cellular therapy recipients

Conditions: Cancer; Hematopoietic System--Cancer; Transplant-Related Cancer; Solid Tumor Malignancy; Hematologic Malignancy; Solid Organ Transplant; Hematopoietic Cell Transplant; Cellular Therapy

Summary: this study is being done because the investigators would like to learn more about how well the covid-19 vaccine works in participants with cancer or those who have received a transplant or cellular therapy. primary objective assess the immunogenicity to covid-19 vaccination in patients with cancer and/or transplant and cellular therapy (tct) recipients. secondary objectives * evaluate the antibodies response to covid-19 vaccination in immunocompromised patients. * evaluate the t cell response to covid-19 vaccination in immunocompromised patients. exploratory objectives * assess incidence and severity of covid-19 infections by 6 months following immunization with a sars cov-2 vaccine. * assess the durability immune response to covid-19 vaccination. * assess the immunogenicity of covid-19 vaccination in immunocompetent children and adolescents without cancer and have not undergone transplant or received cellular therapy.

the investigator will collect a blood sample (about 1 teaspoon each time) from the participant when the participant receive the covid-19 vaccine(s) as well as an additional blood samples 6 months after the last covid-19 vaccine. the participant will be on the study for about 6 months after the last vaccine. after the six-month blood sample is collected, the participant will be off study.

Eligibility criteria:
inclusion criteria: * patient receiving care at st. jude children's hospital or le bonheur children's hospital * less than 24 years old at the time of enrollment (day 0) * planning to receive a covid-19 vaccine as part of clinical care * patient is one of the following: 1. diagnosed with a hematological malignancy (group a), or 2. received a hematopoietic cell transplant or cellular therapy (group b), or 3. diagnosed with a solid tumor malignancy (group c). 4. received a solid organ transplant (group d), or 5. does not have cancer and has not received any type of transplant (group e) * willing and able to provide informed consent exclusion criteria: * received a covid-19 vaccine prior to enrollment (day 0).
in vitro interaction between ticagrelor and its active metabolite and their effects on salicylic acid

Conditions: Cardiovascular Diseases

Summary: this is a in-vitro study to evaluate the pharmacodynamic interaction between ticagrelor and its active metabolite (ar-c124910xx) and their effects on the pharmacodynamics of salicylic acid. the study consist of two parts of in-vitro study as follows; * part 1 : in-vitro study to evaluate the pharmacodynamic interaction between ticagrelor and its active metabolite. * part 2 : in vitro study to evaluate the pharmacodynamic interaction between ticagrelor and its active metabolite and their effect on the pharmacodynamics of salicylic acid on platelet aggregation tests with the agonist of arachidonic acid.

this is a in-vitro study to evaluate the pharmacodynamic interaction between ticagrelor and its active metabolite (ar-c124910xx) and their effects on the pharmacodynamics of salicylic acid. the study consist of two parts of in-vitro study as follows; * part 1 : in-vitro study to evaluate the pharmacodynamic interaction between ticagrelor and its active metabolite. platelet aggregation tests with the agonist of adenosine diphosphate(adp) will be assessed on the in-vitro mixtures of blank plasma and randomized paired concentrations of ticagrelor + ar-c124910xx. * part 2 : in vitro study to evaluate the pharmacodynamic interaction between ticagrelor and its active metabolite. platelet aggregation tests with the agonist of arachidonic acid will be assessed on the in-vitro mixtures of blank plasma plus randomized paired concentrations of ticagrelor and ar-c124910xx and the invitro mixtures with blank plasma and ticagrelor + ar-c124910xx + salicylic acid.

Eligibility criteria:
inclusion criteria: * subjects with body weight more than 50 kg and within 20% of the ideal body weight: ideal body weight = (height\[cm\] - 100)\*0.9. * subjects who have received and understood completely the information regarding the current study and given written informed consents to voluntarily participate in the study and followed all instructions specified in the protocol. exclusion criteria: * subjects who have a history or presence of any clinically significant diseases. * subjects who have any congenital or acquired haematological diseases. * subjects who had whole blood donation within the last 2 months and component blood donation within the last month. * subject who took any concomitant medication including non-steroidal antiinflammatory drugs(nasids) and vitamins currently or within 7 days prior to blood sampling.

Keywords: platelet aggregation cardiovascular diseases salicylic acid
inhaler technique in elderly patients: impact on disease exacerbations

Conditions: Asthma; COPD

Summary: introduction copd and asthma affect more than 10% of the population. most patients use their inhaler incorrectly, mainly the elderly, thereby becoming more susceptible to poor clinical control and exacerbations. placebo device training is regarded as one of the best teaching methods, but there is scarce evidence to support it as the most effective one to improve major clinical outcomes. our objective is to perform a single-blinded rct to assess the impact of this education tool in these patients. methods and analysis a multicentre single-blinded rct will be set, comparing a placebo-device training programme versus usual care, with a one-year follow-up, in elderly patients with asthma or copd. intervention will be provided at baseline, and after 3 and 6 months, with interim analysis at an intermediate time point. exacerbation rates were set as primary outcomes, and quality of life, adherence rates, clinical control and respiratory function were chosen as secondary outcomes. a sample size of 146 participants (73 in each arm) was estimated as adequate to detect a 50% reduction in event rates. two-sample proportions chi-squared test will be used to study primary outcome and subgroup analysis will be carried out according to major baseline characteristics. discussion the investigators expect to confirm that inhaler performance education will significantly reduce exacerbation rate and improve clinical and functional control. ethics and dissemination: every participant will sign a consent form. a data safety monitoring board will be set up to evaluate data throughout the study and to monitor stop earlier criteria. identity of all participants will be protected. results will be presented in scientific meeting and published in peer-reviewed journals.


Eligibility criteria:
inclusion criteria: * patients with a diagnosis of copd or asthma, medicated with any kind of inhaler device (pressurized metered dose inhaler (pmdi) with or without spacer, dry powder inhaler (dpi) or soft mist), aged ≥65 years and being a regular user of primary health care services (defined as having at least one consultation performed in the last two years with his/her own family doctor). in order to minimize diagnostic inaccuracy, asthma and copd diagnosis will be reviewed in every participant at baseline prior to enrolment and according to gina and gold strategies. exclusion criteria: * severe or acute illness (such as unstable cardiovascular status, unstable angina, recent myocardial infarction (within one month) or pulmonary embolism, haemoptysis of unknown origin, recent pneumothorax (within one month), recent thoracic, abdominal or eye surgery (within one month), acute nausea or vomiting, severe respiratory distress, dementia). patients with intermittent asthma, as well as copd patients with mild obstruction (gold class i) will be excluded, since these patients do not need to take inhaler medication on a daily basis, and tend to have a low frequency of disease exacerbations.

Keywords: nebulizers and vaporizers